Rheumatology Advance Access originally published online on July 14, 2009
Rheumatology 2009 48(9):1178; doi:10.1093/rheumatology/kep180
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Comment on: Possible miliary tuberculosis during adalimumab therapy with negative
-IFN release assays: reply
1Rheumatology Department, Queen Alexandra Hospital, Portsmouth and 2Rheumatology Department, Basingstoke and North Hampshire NHS Trust, Basingstoke, UK
Correspondence to: Alison L. Endean, Queen Alexandra Hospital, Southwick Hill Road, Cosham, Portsmouth PO6 3LY, UK. E-mail: alisonendean@doctors.org.uk
| The first 10% of the full text of this article appears below. |
SIR, We would like to thank Mangat et al. [1] for their interest in our article [2] and would like to make the following comments.
We did not isolate any organisms including non-tuberculous mycobacterium